Jaktinib hydrochloride is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II drugs for Rheumatoid Arthritis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Jaktinib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Jaktinib hydrochloride overview
Jaktinib is under development for the treatment of graft versus host disease, rheumatoid arthritis, plaque psoriasis, idiopathic pulmonary fibrosis, autoimmune disorders, novel coronavirus pneumonia (COVID-19), myelofibrosis including primary myelofibrosis (factor PMF), polycythemia vera myelofibrosis post (Post-PV-MF) or essential thrombocytosis myelofibrosis (Post-ET-MF), alopecia areata and atopic dermatitis. The drug candidate is formulated as a tablet and cream form which is administered through oral and topical route. It acts by targeting tyrosine protein kinase JAK1, JAK2 and JAK3. It is chemically new drug. The drug candidate was also under development for autoimmune disease lupus, myelodysplastic syndrome.
Suzhou Zelgen Biopharmaceutical overview
Suzhou Zelgen Biopharmaceutical (Zelgen) is a pharmaceutical company that carries out research and development and production of innovative medicines. The company’s pipeline products include Donafenib Tablet, Rh Thrombin, gecacitinib hydrochloride tablets, ZG0895, ZGS15, ZG006, ZG2001, ZG1905, ZGGS001, RhTSH and gecacitinib hydrochloride Cream, ZG19018 Tablet, ZG005 Powder for Injection and ZGGS18. Its therapeutic areas include liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal cancer, myeloproliferative neoplasms cancers, hematological tumors, hemorrhage, immune-inflammatory diseases, liver and gallbladder diseases and other therapeutic areas. Zelgen operates its drug research and development center in China and the US. Zelgen is headquartered in Kunshan, Jiangsu, China.
For a complete picture of Jaktinib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
